Acorda Therapeutics, Inc. (ACOR)

CAPS Rating:

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

View Ticker Page (ACOR)

Results 1 - 10 of 30 : 1 2 3

Recs

5

Avatar BoringIsNormal (28.06) Submitted: 3/18/08 3:37 PM : Start Price: $18.52 ACOR Score: 24.57

Once they get Phamberine XR approved by the FDA the stock will shine, if not... well it's pretty much the end, they can't stay afloat with zanflax especially with all the debt they are using for research into XR.

Report this Post Replies: 0 | Reply | Permalink

Recs

3

Avatar wisedrdave (< 20) Submitted: 7/16/07 12:15 AM : Start Price: $20.58 ACOR Score: 25.40

Biotech company in phase III of new drug for MS. More on the way for stroke, head injury. Current widely used Zanaflex sales keeps downside minimal. Expect to be a big winner within year.

Report this Post Replies: 0 | Reply | Permalink

Recs

2

Avatar egenesis (44.45) Submitted: 8/16/07 2:04 PM : Start Price: $16.77 ACOR Score: 38.65

One of the two clinical trials required for approval of MS drug has been completed with statistically significant results, which was the reason for the stock runup. Company started 2nd trial already which should be completed in a year or so. There ...

Report this Post Replies: 0 | Reply | Permalink

Recs

2

Avatar stratton6 (99.65) Submitted: 4/12/07 12:36 PM : Start Price: $21.58 ACOR Score: 16.64

Acorda has a breakthrough drug that seems to improve the quality of life for MS patients. This is not a thing to take lightly. The FDA knows this and will generally work with companies that need unusual endpoint determinations to prove efficacy for...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar Jeffreyw (49.76) Submitted: 6/24/08 12:45 PM : Start Price: $20.28 ACOR Score: 17.08

Their work seems to have some promising developments therapies that can have a wide-ranging benefit in periferal areas of treatment.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar KevinatUCLA (98.23) Submitted: 4/14/08 8:13 AM : Start Price: $19.26 ACOR Score: -20.73

This stock is junk.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar deuspecuniae (59.15) Submitted: 4/23/08 11:15 PM : Start Price: $19.72 ACOR Score: 21.60

This stock has been stuck into a classic pattern for the year. We're heading back into the upper $20's this summer. A recession at home isn't going to scare anyone into selling this gem.

Report this Post Replies: 0 | Reply | Permalink